Literature DB >> 12757272

Whither seniors' pharmacare: lessons from (and for) Canada.

Steven G Morgan1, Morris L Barer, Jonathan D Agnew.   

Abstract

Canada's provincial governments have, until relatively recently, provided virtually all seniors with generous prescription drug coverage. Managers of these programs have implemented a variety of policies to contain spending while ensuring access to necessary medicines. Some of these policies have been successful in temporarily slowing cost growth. However, the lack of comprehensive utilization management tools has resulted in ongoing spending increases that now constitute a threat to the sustainability of a public drug subsidy for Canadian seniors. Sustainable and equitable pharmacare programs require the political willingness to confront opposition to policies that will, if successful, contain program costs without obstructing access.

Mesh:

Year:  2003        PMID: 12757272     DOI: 10.1377/hlthaff.22.3.49

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  16 in total

1.  The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

Authors:  Paul V Grootendorst; John K Marshall; Anne M Holbrook; Lisa R Dolovich; Bernie J O'Brien; Adrian R Levy
Journal:  Health Serv Res       Date:  2005-10       Impact factor: 3.402

2.  Prescription drug expenditures and population demographics.

Authors:  Steven G Morgan
Journal:  Health Serv Res       Date:  2006-04       Impact factor: 3.402

3.  The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study.

Authors:  Steven G Morgan; Emilie J Gladstone; Deirdre Weymann; Nadia Khan
Journal:  CMAJ Open       Date:  2017-03-03

4.  Use of product listing agreements by Canadian provincial drug benefit plans.

Authors:  Steven G Morgan; Melissa K Friesen; Paige A Thomson; Jamie R Daw
Journal:  Healthc Policy       Date:  2013-05

5.  Money left on the table: generic drug prices in Canada.

Authors:  Michael R Law
Journal:  Healthc Policy       Date:  2013-02

Review 6.  Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.

Authors:  Yoko Murphy; Emily Wilson; Elliot M Goldner; Benedikt Fischer
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

7.  National pharmacare: Time to move forward.

Authors:  Leila Salehi
Journal:  Can Fam Physician       Date:  2016-07       Impact factor: 3.275

8.  [Assurance-médicaments nationale: Le moment d'aller de l'avant].

Authors:  Leila Salehi
Journal:  Can Fam Physician       Date:  2016-07       Impact factor: 3.275

9.  Is There a Tension between Clinical Practice and Reimbursement Policy? The Case of Osteoarthritis Prescribing Practices in Ontario.

Authors:  Parminder S Raina; Amiram Gafni; Sandra Bell; Susan Grant; Rolf J Sebaldt; Aimei Fan; Annie Petrie; Kevin Skilton
Journal:  Healthc Policy       Date:  2007-11

10.  Family physician attitudes about prescribing using a drug formulary.

Authors:  L Suzanne Suggs; Parminder Raina; Amiram Gafni; Susan Grant; Kevin Skilton; Aimei Fan; Karen Szala-Meneok
Journal:  BMC Fam Pract       Date:  2009-10-16       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.